Sun Pharma recalls select eye drops in India after contamination concern

Sun Pharma has halted billing and distribution of specified eye-drop products, asking Indian distributors to report inventory and return all stocks as a precaution following a contamination scare.

— Source publishedSat, 1 Aug, 2026, 20:49 IST·First seen Sat, 1 Aug, 2026, 21:04 IST·Source ET Small Business

What happened

Sun Pharma has halted distribution and recalled specified eye-drop products from Indian channels as a precaution following a contamination scare, asking

Key facts

  • July 17
  • Eye Drops 5ML
  • Depopred 2ML
  • Lotepred 1%
  • Lotepred LS 0.2%
  • Nepalact OD Eye Drops 3ML

Why this matters

The disruption highlights the strategic value of diversified ophthalmic suppliers and robust quality-control diligence in any pharma partnership, sourcing, or acquisition evaluation.

What to watch

  • Sun Pharma disclosure of affected product names, batch numbers, manufacturing sites, and recall geography.
  • CDSCO or state drug-controller notices, sampling results, inspection actions, or mandatory recall directions.
  • Any reports of patient adverse events, infection cases, pharmacist complaints, or medical advisories tied to the products.
  • Whether the halt remains limited to billing and distribution or expands to a formal consumer-level recall.
  • Stock-out rates, substitute-product fill rates, and price changes across independent chemists, chains, hospitals, and e-pharmacies.
  • Distributor compliance speed and evidence of recalled inventory re-entering secondary channels.
  • Freeze sale, billing, transfers, and e-commerce fulfillment for the specified batches; isolate stock by batch and expiry date.
  • Reconcile distributor, pharmacy, hospital, and online inventory quickly and document return-chain custody.
  • Notify pharmacists and customer-service teams of affected SKUs, approved substitutes, refund procedures, and escalation protocols for consumer complaints.
  • Increase orders of clinically comparable eye-drop alternatives while monitoring supplier capacity and local price movement.
  • Review private-label and category assortment exposure to Sun Pharma ophthalmic products and update availability messaging across digital and physical channels.